Ramelteon,
C16H21NO2,
and molecular mass of 259.343 g/mol is marketed as Rozerem
by Takeda Pharmaceuticals North America, is the first in a
new class of sleep agents that selectively binds to the melatonin
receptors in the suprachiasmatic nucleus (SCN), versus binding
to GABA A receptors, such as with drugs like zolpidem, eszopiclone, and zaleplon. Ramelteon is approved
by the FDA for long-term use. For
complete text click here.